Oral Testosterone Undecanoate Formulation for Steady Serum Levels
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current testosterone replacement therapies for hypogonadism, such as intramuscular injections, topical gels, and oral methyltestosterone, are associated with pain, skin irritation, liver toxicity, and poor compliance due to inadequate bioavailability and fluctuating serum testosterone levels, with no approved oral formulation of testosterone esters providing effective and sustained serum levels.
Innovation Solution
An oral pharmaceutical composition comprising testosterone undecanoate solubilized in a carrier with a specific ratio of lipophilic and hydrophilic surfactants, which upon administration, achieves steady-state serum testosterone levels within the eugonadal range of 300-1100 ng/dL, avoiding high peak concentrations and maintaining consistent levels over time.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If testosterone esters with long carbon chains (14 or more carbons) are used to enable lymphatic absorption and reduce first-pass metabolism, then bioavailability is improved, but the rate and extent of hydrolysis by esterases decreases, resulting in poor pharmacological activity
Solution Approach 1:
The patent changes the carbon chain length parameter of the testosterone ester to C11 (undecanoate), which is shorter than the traditional C14-C24 long-chain esters. This parameter modification allows the ester to be absorbed via lymphatic circulation (improving bioavailability) while maintaining a reasonable hydrolysis rate (preserving pharmacological activity). The specific C11 chain length represents an optimized compromise between these two competing requirements.
Solution Approach 2:
The patent employs a self-emulsifying delivery system that dynamically adapts to the gastrointestinal environment. The formulation contains surfactants and lipids that automatically form fine emulsion droplets upon contact with gastric fluids, enhancing solubilization and absorption without requiring external intervention. This dynamic self-adjustment mechanism optimizes bioavailability based on physiological conditions.
2Ease of operation
If testosterone esters are administered orally, then ease of operation is improved, but first-pass intestinal and hepatic metabolism causes poor bioavailability
Solution Approach 1:
The patent introduces a self-emulsifying delivery system as an intermediary between the testosterone undecanoate and the gastrointestinal tract. This system includes surfactants (e.g., Tween 80, Span 85) and lipids that form protective emulsion droplets, shielding the ester from premature metabolism while facilitating absorption. The delivery system acts as a mediator that enables oral administration to be effective despite the presence of metabolic enzymes.
Solution Approach 2:
The patent utilizes the hydraulic principles of emulsion formation and fluid dynamics to overcome first-pass metabolism. The self-emulsifying formulation creates fine droplets (1-10 micrometers) that enhance surface area for absorption and facilitate lymphatic uptake. The fluid mechanical properties of the emulsion (viscosity, interfacial tension) are optimized to ensure stable transport through the gastrointestinal tract and efficient absorption.
3Reliability
If testosterone esters are solubilized in aqueous media, then absorption is enabled, but the esters precipitate or come out of solution in vivo due to poor water solubility
Solution Approach 1:
The patent creates a composite self-emulsifying system combining testosterone undecanoate with surfactants (hydrophilic-lipophilic balance materials) and lipids. This composite formulation leverages the amphiphilic properties of the surfactants to solubilize the hydrophobic testosterone ester in aqueous gastrointestinal fluids. The composite structure remains stable in vivo, preventing precipitation while enabling absorption.
Solution Approach 2:
The patent exploits phase transition principles through the self-emulsification process. Upon contact with gastric fluids, the formulation undergoes a phase transition from a separated oil-phase system to a fine emulsion droplet system. This phase change enhances solubilization and stability in the aqueous environment. The emulsion droplets maintain a controlled interface between the lipophilic ester and hydrophilic gut fluids, preventing macroscopic phase separation and precipitation.
4Ease of operation
If methyltestosterone is used as oral therapy, then ease of operation is improved, but liver toxicity occurs with significant incidence
Solution Approach 1:
The patent extracts the problematic C17-methyl modification from the testosterone molecule that causes liver toxicity in methyltestosterone. By using unmodified testosterone undecanoate ester instead of methyltestosterone, the formulation eliminates the hepatotoxic metabolic pathway while maintaining oral administrability. The C17 position remains free (unmethylated), allowing for safer metabolic processing through the lymphatic route.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition provides sustained serum testosterone levels within the therapeutic range, reducing diurnal variation and minimizing liver toxicity risks, while allowing for flexible dosing and improved patient compliance.
Implementation Method 1
The formulations are designed to be self-emulsifying drug delivery systems (SEDDS) so that a TU-containing emulsion (or dispersion) is formed upon mixing with intestinal fluids in the gastrointestinal tract.
Implementation Method 2
The formulations comprise a T-ester dissolved in a mixture comprising one or more lipophilic surfactants and one or more hydrophilic surfactants.
Implementation Method 3
Fatty acid esters of long carbon chains (i.e., 14 or more carbons) may be absorbed by intestinal lymphatics
Data Source
AI summary
A pharmaceutical formulation of testosterone undecanoate is provided. Methods of treating a testosterone deficiency or its symptoms with the inventive formulations are also provided.